265 related articles for article (PubMed ID: 27931230)
1. Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients.
Tanaka K; Joyama S; Chuman H; Hiraga H; Morioka H; Yoshikawa H; Hosaka M; Takahashi M; Kubo T; Hatano H; Kaya M; Toguchida J; Nishida Y; Nagano A; Tsumura H; Iwamoto Y
World J Surg Oncol; 2016 Dec; 14(1):306. PubMed ID: 27931230
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C
PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study.
Hara H; Kawamoto T; Fukase N; Kawakami Y; Takemori T; Fujiwara S; Kitayama K; Nishida K; Kuroda R; Akisue T
BMC Cancer; 2019 Jul; 19(1):725. PubMed ID: 31337342
[TBL] [Abstract][Full Text] [Related]
4. A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.
Seidman AD; Chan S; Wang J; Zhu C; Xu C; Xu B
Oncologist; 2014 May; 19(5):443-52. PubMed ID: 24705980
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y
Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
7. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
Lee EM; Rha SY; Lee J; Park KH; Ahn JH
Cancer Chemother Pharmacol; 2012 Mar; 69(3):635-42. PubMed ID: 21959979
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study.
Choi Y; Yun MS; Lim SH; Lee J; Ahn JH; Kim YJ; Park KH; Park YS; Lim HY; An H; Suh DC; Kim YH
Cancer Res Treat; 2018 Jan; 50(1):175-182. PubMed ID: 28361521
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.
Nielsen DL; Bjerre KD; Jakobsen EH; Cold S; Stenbygaard L; Sørensen PG; Kamby C; Møller S; Jørgensen CL; Andersson M
J Clin Oncol; 2011 Dec; 29(36):4748-54. PubMed ID: 22084374
[TBL] [Abstract][Full Text] [Related]
11. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.
Navid F; Willert JR; McCarville MB; Furman W; Watkins A; Roberts W; Daw NC
Cancer; 2008 Jul; 113(2):419-25. PubMed ID: 18484657
[TBL] [Abstract][Full Text] [Related]
12. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
13. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
[TBL] [Abstract][Full Text] [Related]
14. TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.
Jørgensen CL; Bjerre C; Ejlertsen B; Bjerre KD; Balslev E; Bartels A; Brünner N; Nielsen DL
BMC Cancer; 2014 May; 14():360. PubMed ID: 24884504
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
Bay JO; Ray-Coquard I; Fayette J; Leyvraz S; Cherix S; Piperno-Neumann S; Chevreau C; Isambert N; Brain E; Emile G; Le Cesne A; Cioffi A; Kwiatkowski F; Coindre JM; Bui NB; Peyrade F; Penel N; Blay JY;
Int J Cancer; 2006 Aug; 119(3):706-11. PubMed ID: 16496406
[TBL] [Abstract][Full Text] [Related]
16. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Kaya AO; Büyükberber S; Ozkan M; Alkiş N; Sevinc A; Ozdemir NY; Alici S; Esbah O; Berk V; Camci C; Ulas A; Coskun U; Benekli M;
Asian Pac J Cancer Prev; 2012; 13(2):463-7. PubMed ID: 22524807
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma.
Naiki T; Kawai N; Hashimoto Y; Okamura T; Ando R; Yasui T; Okada A; Etani T; Tozawa K; Kohri K
Int J Clin Oncol; 2014; 19(3):516-22. PubMed ID: 23749066
[TBL] [Abstract][Full Text] [Related]
19. Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.
Hensley ML
Curr Opin Oncol; 2010 Jul; 22(4):356-61. PubMed ID: 20520541
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Kontopodis E; Kentepozidis N; Christophyllakis Ch; Boukovinas I; Kalykaki A; Kalbakis K; Vamvakas L; Agelaki S; Kotsakis A; Vardakis N; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2015 Jan; 75(1):153-60. PubMed ID: 25398698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
